West China Hospital COVID-19 vaccine
Vaccine description
TargetSARS-CoV-2
Vaccine typeProtein subunit
Clinical data
Routes of
administration		Intramuscular
Identifiers
DrugBank

West China Hospital COVID-19 vaccine is a COVID-19 vaccine candidate developed by Jiangsu Province Centers for Disease Control and Prevention, West China Hospital and Sichuan University.

Clinical trials

In August 2020, WestVac Biopharma started phase I clinical trials with 168 participants in China.[1]

In November, WestVac Biopharma started phase II clinical trials with 960 participants in China[2] In February 2021, WestVac Biopharma started phase IIb clinical trials with 4,000 participants in China. Later, WestVac Biopharma is no longer on phase IIb clinical trial.[3]

In June 2021, WestVac Biopharma started phase III trials with 40,000 participants including Indonesia, Kenya, and the Philippines.[4]

Children and adolescents trials

In August 2021 WestVac Biopharma started phase I/II trials with 600 participants for children and adolescents aged 6-17.[5]

References

  1. ↑ "Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)". clinicaltrials.gov. United States National Library of Medicine. 8 February 2021. Retrieved 20 March 2021.
  2. ↑ "A Phase II Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)". clinicaltrials.gov. United States National Library of Medicine. Retrieved 20 March 2021.
  3. ↑ "Phase IIb Clinical Trial of Recombinant Novel Coronavirus Pneumonia (COVID-19) Vaccine (Sf9 Cells)". clinicaltrials.gov. United States National Library of Medicine. Retrieved 20 March 2021.
  4. ↑ "A Global Phase III Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells)". clinicaltrials.gov. United States National Library of Medicine. Retrieved 15 May 2021.
  5. ↑ "Phase I/II Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells) in Children and Adolescents". clinicaltrials.gov. United States National Library of Medicine. Retrieved 20 August 2021.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.